Mulder M, van der Boom H, de Knijff P, Braam C, van den Maagdenberg A, Leuven J A, Havekes L M
TNO Institute of Prevention and Health Research, Gaubius Laboratory, Leiden, The Netherlands.
Atherosclerosis. 1994 Aug;108(2):183-92. doi: 10.1016/0021-9150(94)90113-9.
The APOE2(Lys146-->Gln) allele behaves like a dominant trait in the expression of familial dysbetalipoproteinemia (FD) (Smit et al., J. Lipid Res. 1990; 31: 45-53). FD patients carrying the APOE2(Lys146-->Gln) allele exhibit less elevated cholesterol to triglyceride ratios in the d < 1.019 g/ml lipoprotein density fraction as compared to classical FD patients displaying homozygosity for the APOE2(Arg158-->Cys) allele (0.8 vs. 1.4). Upon treatment of complete serum with lipoprotein lipase (LPL), the mean cholesterol to triglyceride molar ratio of the d < 1.019 g/ml lipoprotein fraction in these FD patients increased only marginally (from 0.8 to 1.1), as compared with that of classical FD subjects (from 1.4 to 2.6) and non-FD control subjects (from 0.7 to 1.5). In order to obtain further evidence for an inefficient lipolysis of the d < 1.019 g/ml lipoprotein fraction in APOE*2(Lys146-->Gln) carriers, possibly in combination with a less efficient cholesteryl ester transfer protein (CETP) activity, blood samples of APOE2(Lys146-->Gln) allele carrying FD patients were analysed and compared with classical FD patients and controls. In the APOE2(Lys149-->Gln) allele carrying FD patients were analysed and compared with classical FD patients and controls. In the APOE2(Lys146-->Gln) FD patients, the increase in plasma cholesterol was mainly confined to the very low density lipoprotein (VLDL) fraction, whereas in classical FD patients, the levels of cholesterol in the intermediate density lipoprotein (IDL) fraction was also dramatically increased (ratios of VLDL to IDL cholesterol are 4.7 and 2.6, respectively). Family analyses of the APOE2(Lys146-->Gln) FD subjects showed that the apo E to apo B ratio in the d < 1.019 g/ml lipoprotein fraction of allele carriers is 3.5 times as high as that found in non-carriers (2.8 vs. 0.8, by wt.). Also, in the APOE*2(Lys146-->Gln) allele carrying family members, the ratio of cholesterol to triglyceride of the d < 1.019 g/ml lipoprotein fraction is less markedly elevated upon addition of LPL when compared to that in non-carrying controls (from 1.1 to 1.8 vs 0.7 to 1.6). The efficiency of the d < 1.019 g/ml lipoprotein fraction of APOE*2(Lys146-->Gln) FD patients to compete with low density lipoprotein (LDL) for binding to the LDL receptor is intermediate to that of controls and classical APOE2(Arg158-->Cys) homozygous FD patients. These findings suggest that in APOE*2(Lys146-->Gln) allele carriers, the conversion of VLDL into IDL is impaired due to an inefficient lipolysis, possibly in combination with a retarded CETP activity.(ABSTRACT TRUNCATED AT 250 WORDS)
载脂蛋白E2(Lys146→Gln)等位基因在家族性异常β脂蛋白血症(FD)的表达中表现为显性性状(斯密特等人,《脂质研究杂志》1990年;31:45 - 53)。与表现为载脂蛋白E2(Arg158→Cys)等位基因纯合子的典型FD患者相比,携带载脂蛋白E2(Lys146→Gln)等位基因的FD患者在d<1.019 g/ml脂蛋白密度组分中的胆固醇与甘油三酯比值升高程度较低(0.8对1.4)。用脂蛋白脂肪酶(LPL)处理全血清后,这些FD患者d<1.019 g/ml脂蛋白组分的平均胆固醇与甘油三酯摩尔比仅略有增加(从0.8增至1.1),而典型FD受试者(从1.4增至2.6)和非FD对照受试者(从0.7增至1.5)的该比值增加明显。为了进一步证明携带载脂蛋白E2(Lys146→Gln)的个体中d<1.019 g/ml脂蛋白组分的脂解效率低下,可能与胆固醇酯转运蛋白(CETP)活性较低有关,对携带载脂蛋白E2(Lys146→Gln)等位基因的FD患者的血样进行了分析,并与典型FD患者和对照进行比较。在对携带载脂蛋白E2(Lys149→Gln)等位基因的FD患者进行分析并与典型FD患者和对照进行比较时发现,在携带载脂蛋白E2(Lys146→Gln)的FD患者中,血浆胆固醇的升高主要局限于极低密度脂蛋白(VLDL)组分,而在典型FD患者中,中间密度脂蛋白(IDL)组分中的胆固醇水平也显著升高(VLDL与IDL胆固醇的比值分别为4.7和2.6)。对携带载脂蛋白E2(Lys146→Gln)的FD受试者的家系分析表明,等位基因携带者d<1.019 g/ml脂蛋白组分中的载脂蛋白E与载脂蛋白B的比值是非携带者的3.5倍(按重量计为2.8对0.8)。此外 在携带载脂蛋白E2(Lys146→Gln)等位基因的家庭成员中,与非携带对照相比,添加LPL后d<1.019 g/ml脂蛋白组分的胆固醇与甘油三酯比值升高不太明显(从1.1增至1.8对从0.7增至1.6)。携带载脂蛋白E2(Lys146→Gln)的FD患者d<1.019 g/ml脂蛋白组分与低密度脂蛋白(LDL)竞争结合LDL受体的效率介于对照和典型载脂蛋白E2(Arg158→Cys)纯合FD患者之间。这些发现表明,在携带载脂蛋白E2(Lys146→Gln)等位基因的个体中,由于脂解效率低下,可能与CETP活性延迟有关,VLDL向IDL的转化受损。(摘要截选至250字)